Clinical trials: copd or chronic obstructive
Pulmonary Disease, Chronic Obstructive
A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-1)
The study primarily aims to demonstrate the superiority of GSK5784283 as an add-on therapy compared to placebo in reducing the annualized rate of moderate and severe chronic obstructive pulmonary disease (COPD) exacerbations.
- Trial name
- NCT07780669
- Testing
- GSK5784283, Standard of care
- Where
- 2 sites in United States
- Volunteers
- 624 people
- Sponsor
- GlaxoSmithKline
Asthma, Chronic Obstructive Pulmonary Disease (COPD)
A Study to Assess the Effect of Particle Size of AZD7594 on Pharmacokinetics (PK) After a Single Inhaled Dose When Administered Using the Dry Powder Inhaler in Healthy Volunteers
This study is an open label, randomized, three-way crossover study to assess the effect of particle size on the PK and safety of single inhaled doses of AZD7594 in healthy subjects (males aged 18 to 55 years [inclusive]).
- Trial name
- NCT02928354
- Testing
- Treatment A - AZD7594, Treatment B - AZD7594, Treatment C - AZD7594
- Where
- Germany
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
A Study to Evaluate Efficacy and Safety Profile of Zabofloxacin Tablet 400mg and Moxifloxacin Tablet 400mg
The purpose of this study is to Evaluate the Efficacy and Safety Profiles of oral multiple dose of Zabofloxacin Tablet 400 mg.
- Trial name
- DW224-III-3 (NCT01658020)
- Testing
- Zabofloxacin, Moxifloxacin
- Where
- South Korea
- Volunteers
- 345 people
- Sponsor
- Dong Wha Pharmaceutical Co. Ltd.
COPD, ILD
Individualized Plan for Improving Adherence to Portable Oxygen Therapy in Patients With Respiratory Pathology
Pilot study with patients with prescription of portable oxygen therapy, to test the impact on adherence of a patient-centered empowerment program, with contents on the nature of the respiratory pathology, the symptom of dyspnea…
- Conditions
- COPD, ILD, Dyspnea
- Trial name
- PIMAOX (NCT04691336)
- Testing
- Educational and Training with counselling
- Where
- Spain
- Volunteers
- 22 people
- Sponsor
- Air Liquide Healthcare Spain
Chronic Obstructive Pulmonary Disease
The Study Will Evaluate the Effect of AZD9164 in Patients With Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease (COPD) is a chronic respiratory condition with deteriorating lung function over the years. Patients with COPD experience symptoms of shortness of breath, cough and sputum production.
- Trial name
- LaCrossE (NCT00939211)
- Testing
- AZD9164, Tiotropium
- Where
- 3 sites in Sweden
- Volunteers
- 25 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
DISKUS vs. ELLIPTA Device Preference Study in Chronic Obstructive Pulmonary Disease (COPD)
Subjects who have not used the ELLIPTA™ inhaler nor the DISKUS™ inhaler in the past 6 months will be screened to participate in the study.
- Trial name
- NCT01868009
- Testing
- ELLIPTA, DISKUS
- Where
- 17 sites in United States
- Volunteers
- 287 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Neutrophil Imaging in Healthy Subjects Following Lipopolysaccharide or Saline Challenge and in Subjects With Chronic Obstructive Pulmonary Disease
This is an exploratory study to further develop an imaging platform for the assessment of whole lung neutrophil retention. The primary objective of the study is to quantify and compare neutrophil retention in the lungs of…
- Trial name
- NCT02551614
- Testing
- Lipopolysaccharide challenge, Saline challenge, Labelled neutrophils and Imaging assessment
- Where
- 2 sites in United Kingdom
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease (COPD)
A Study Comparing the Effects of Trimbow to Fostair in COPD
A randomised, open label 2-way cross-over study to compare the effects of inhaled Beclometasone/Formoterol/Glycopyrronium (TRIMBOW) pMDI to Beclometasone/Formoterol (FOSTAIR) pMDI on hyperinflation and expiratory flow limitation…
- Trial name
- TRIFLOW (NCT03842904)
- Testing
- Trimbow pMDI, Fostair pMDI
- Where
- United Kingdom
- Volunteers
- 23 people
- Sponsor
- Medicines Evaluation Unit Ltd
Chronic Obstructive Pulmonary Disease
PT003 MDI Dose Confirmation Study
The primary objective of this study is to demonstrate efficacy of PT003 MDI relative to its individual components (PT001 MDI and PT005 MDI) in patients with moderate to severe chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT01349816
- Testing
- PT003, PT001, PT005
- Where
- 13 sites in United States
- Volunteers
- 185 people
- Sponsor
- Pearl Therapeutics, Inc.
Pulmonary Disease, Chronic Obstructive
A Study to Evaluate the Effect of the Combination of Umeclidinium (UMEC) and Vilanterol (VI) on Exercise Endurance Time (EET) in Participants With Chronic Obstructive Pulmonary Disease (COPD)
This is a multicenter, randomized, double-blind, placebo-controlled, 2-period, complete block design cross-over study. The purpose of this study is to evaluate the effect of UMEC/VI 62.5/25 microgram (mcg) on EET as measured by…
- Trial name
- NCT02275052
- Testing
- UMEC/VI DPI, Albuterol/salbutamol MDI
- Where
- 10 sites in United States
- Volunteers
- 198 people
- Sponsor
- GlaxoSmithKline
Alpha1-Antitrypsin Deficiency
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency
The purpose of this study is to evaluate the safety and tolerability of 72 milligrams per kilogram (mg/kg) and 180 mg/kg Alpha-1 15%, administered as a single-dose subcutaneous (SC) infusion and subsequently as weekly SC…
- Trial name
- NCT04722887
- Testing
- Alpha-1 15%, Liquid Alpha1-Proteinase Inhibitor (Human)
- Where
- 5 sites in United States
- Volunteers
- 17 people
- Sponsor
- Grifols Therapeutics LLC
Chronic Obstructive Pulmonary Disease (COPD)
Tiotropium Bromide Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease
A Phase 2, Randomized, Partially-blinded, Parallel Group, Dose-ranging Study to Assess the Pharmacodynamics, Relative Bioavailability, and Safety of Three Doses of Tiotropium Bromide Inhalation Solution in Subjects with Chronic…
- Trial name
- NCT04780984
- Testing
- Tiotropium bromide inhalation solution
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- Nephron Pharmaceuticals Corporation
Myelogenous Leukemia, Chronic, Neoplasms, Myelogenous Leukemia, Acute
An Extension Study of RO5045337 in Participants Participating in Previous Roche-sponsored Cancer Studies
This open-label, extension study is designed to provide continuing treatment with RO5045337 to participants who have completed parent studies NO21279 (NCT00623870), NO21280 (NCT00559533), NP25299 (NCT01164033), NP28021…
- Trial name
- NCT01677780
- Testing
- RO5045337
- Where
- 5 sites in United States, Canada and 1 more
- Volunteers
- 11 people
- Sponsor
- Hoffmann-La Roche
Inflammatory Disorder of the Respiratory Tract, Chronic Obstructive Pulmonary Disorder
SAD/MAD Study of a New Formulation of Nebulised RPL554 in Healthy Subjects and COPD Subjects
The purpose of the study is to assess the safety of single doses and multiple doses of a new formulation of RPL554 in healthy subjects and subjects with chronic obstructive pulmonary disorder.
- Trial name
- NCT02307162
- Testing
- RPL554
- Where
- United Kingdom
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Pulmonary Disease, Chronic Obstructive
Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)
The overall objective of this study is to assess the efficacy and safety of 52 weeks once daily treatment with orally inhaled tiotropium + olodaterol FDC (delivered by the RESPIMAT Inhaler) compared with the individual components…
- Trial name
- NCT01431274
- Testing
- tiotropium + olodaterol, tiotropium, olodaterol
- Where
- 239 sites in United States, Argentina and 23 more
- Volunteers
- 2,624 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Using Salmeterol as Active Control
This study evaluated the safety and efficacy of 26 weeks treatment with indacaterol, placebo or salmeterol in patients with chronic obstructive pulmonary disease.
- Trial name
- NCT00567996
- Testing
- Indacaterol 150 μg, Salmeterol 50 μg
- Where
- 128 sites in Canada, Colombia and 13 more
- Volunteers
- 1,002 people
- Sponsor
- Novartis
Pulmonary Disease, Chronic Obstructive
Efficacy and Safety of Tiotropium Compared to Salmeterol and Placebo in Patients With Chronic Obstructive Bronchitis (COPD)
The objective of this study is to compare the long-term (six month) bronchodilator efficacy and safety of tiotropium inhalation capsules, salmeterol inhalation aerosol and placebo inpatients with COPD.
- Trial name
- NCT02173691
- Testing
- Tiotropium inhalation powder capsules, Salmeterol inhalation aerosol
- Volunteers
- 584 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Phase 2 Study of the Safety and Efficacy of UK-500,001 in Adult Patients With COPD
This initial proof of concept, phase II study aims to assess the safety and efficacy of UK-500,001 for the chronic maintenance treatment of adults with Chronic Obstructive Pulmonary Disease.
- Trial name
- NCT00263874
- Testing
- UK-500,001
- Where
- 28 sites in Argentina, Australia and 8 more
- Volunteers
- 324 people
- Sponsor
- Pfizer
COPD
RUSSE / Russian Spiriva® Safety & Efficacy Study
At the moment, there is hardly any structured safety and efficacy data collection on Tiotropium in Russia. Therefore, the objective of this observational study is to collect and evaluate data on bronchodilator efficacy and safety…
- Trial name
- NCT00613574
- Testing
- tiotropium-bromide
- Where
- 33 sites in Russia
- Volunteers
- 407 people
- Sponsor
- Boehringer Ingelheim
COPD, Comorbidities and Coexisting Conditions
Pragmatic Assessment of the NuvoAir Clinical Service in the Management of Patients With Chronic Obstructive Pulmonary Disease
This is a 12 month study of up to 500 people with COPD to determine if the NuvoAir clinical service leads to lower rates of severe COPD exacerbations, hospitalizations, emergency room visits, and total cost of care compared to a…
- Trial name
- PROMISE (NCT05955482)
- Testing
- NuvoAir Clinical Service
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- NuvoAir Medical PC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.